Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTA01 in severe COVID-19
NCT04644185Phase 3Terminated
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of upanovimab in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Started Mar 2021; status: terminated.
02
Drugs
upanovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04644185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644185.